Rifampicin-Resistant/Multidrug-Resistant Pulmonary Tuberculosis: Individualised Regimens

Multidrug Resistant Tuberculosis WorkshopRIFAMPICIN-RESISTANT/MULTIDRUG RESISTANT PULMONARY TUBERCULOSIS: INDIVIDUALISED REGIMENS

K. Kannan Sivaraman Kannan
Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia

The management of RR/MDR TB has evolved at a very rapid pace since 2016. Newer drugs such as Bedaquiline, Delamanid and Pretomanid has given hope to this devastating scourge. The latest WHO guidelines are all now in line with these new drugs.  But challenges such as availability and cost has made their use not so widespread as wished. All TB patients should be afforded an individualized regimen as far as possible even in the background of a programmatic approach. This is even more true for RR/MDR TB patients. For this lecture ,  I will approach the latest WHO regimes for the all oral ( shorter and longer regimens ) as well as regimens that still use injectables due to the challenges mentioned.